Yatharth Hospital & Trauma Care Services shares fell over 5% on May 25 despite reporting strong double-digit growth in revenue and profit for the March quarter, suggesting investors were concerned about profitability trends and the company’s aggressive expansion-led cost build-up. The stock was trading at ₹818.6, down 5.05%, after touching an intraday low of ₹792.85 on the NSE.
The company reported consolidated revenue from operations of ₹341.56 crore for Q4FY26, up sharply from ₹233.03 crore in the corresponding quarter last year. Profit after tax rose to ₹44.70 crore from ₹38.72 crore YoY.
However, beneath the headline growth numbers, several pressure points appear to have disappointed the Street.
One of the biggest concerns was margin compression. While revenue jumped nearly 47% YoY, operating costs surged at a faster pace due to expansion of new hospitals and ramp-up expenses. Employee benefit expenses climbed to ₹70.10 crore in Q4FY26 versus ₹43.82 crore a year ago, while depreciation and amortisation expenses more than doubled to ₹30 crore from ₹12.87 crore. Other expenses also increased sharply to ₹129.38 crore from ₹86.54 crore.
This meant profit growth failed to keep pace with revenue growth. EBITDA margins weakened despite strong occupancy and expansion-led scale-up, which investors may have interpreted as early signs of near-term pressure from aggressive capacity additions.
Sequentially too, profitability softened. Profit before tax declined to ₹51.95 crore in Q4FY26 from ₹57.10 crore in Q3FY26 even as revenue increased. This suggests operating leverage is yet to fully emerge from newly commissioned hospitals.
Investors also appear cautious about the company’s rapid expansion cycle. During FY26, Yatharth operationalised:
A 300-bed hospital in Model Town, Delhi
A 400-bed hospital in Faridabad
A 150-bed hospital in Agra, expandable to 250 beds.
Additionally, the company disclosed that one of its subsidiaries has entered into a binding term sheet to acquire an under-construction 250-bed hospital in Gurugram.
While these expansions strengthen long-term growth visibility, the market may be factoring in:
Longer gestation periods
Initial occupancy ramp-up risks
Margin dilution from underutilised assets
Higher depreciation and finance costs in the near term
Another factor that may have weighed on sentiment was the sharp increase in total assets and ongoing capex intensity. Consolidated assets expanded to ₹2,281.53 crore as of March 31, 2026, from ₹1,731.17 crore a year earlier. Meanwhile, the company reported investing cash outflows of nearly ₹598 crore during FY26, largely linked to expansion and acquisitions.
Cash and cash equivalents also declined significantly to ₹220.24 crore from ₹360.22 crore YoY.
The continuing Income Tax Department matter disclosed in the filing may also have added to investor caution. The company said assessment orders for AY2014-15 to AY2023-24 had been issued and appeals were filed against them, though management stated it does not expect any material liability.
Overall, while Yatharth Hospital delivered strong revenue growth and healthy headline PAT numbers, the Street appears to have focused more on declining operating efficiency, rising costs, heavy capex commitments, and execution risks associated with multiple simultaneous hospital expansions.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.